What is Protea Biosciences Group?
Protea Biosciences Group operates at the intersection of advanced molecular biology and analytical instrumentation. The company specializes in the development and commercialization of proprietary technologies designed to identify and characterize molecules produced by living cells. Its core portfolio includes the innovative Histology Guided Mass Spec Imaging software suite and the LAESI technology platform, which facilitate precise molecular characterization of biotherapeutics. By providing integrated proteomics, metabolomics, and protein characterization services, Protea serves a diverse clientele ranging from academic research institutions to global pharmaceutical enterprises. The firm's strategic collaborations with prestigious entities such as the Yale University School of Medicine and the Memorial Sloan-Kettering Cancer Center further validate its role as a pivotal player in the advancement of early-stage disease diagnostics and therapeutic development.
How much funding has Protea Biosciences Group raised?
Protea Biosciences Group has raised a total of $44.3M across 2 funding rounds:
Stock Offering
$43.6M
Debt
$691K
Stock Issuance/Offering (2014): $43.6M, investors not publicly disclosed
Debt (2016): $691K, investors not publicly disclosed
Key Investors in Protea Biosciences Group
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Protea Biosciences Group?
With the successful acquisition of this latest capital, Protea Biosciences Group is poised to accelerate its research and development initiatives, particularly in the realm of mass spectrometry imaging and biotherapeutic analysis. The strategic focus will likely shift toward expanding its global sales footprint and deepening its collaborative research agreements to address unmet needs in oncology and personalized medicine. As the company leverages its recent financing, it remains focused on optimizing its bioanalytical reagents and software suites to maintain a competitive edge in the rapidly evolving life sciences market. Future growth will be contingent upon the successful translation of its prototype instrumentation into broader commercial applications and the continued scaling of its service-based revenue model.
See full Protea Biosciences Group company page
